TMU Biomedical Commercialization Center

Organization profile

Organisation profile

宗旨:

促進本校生技醫藥商品化發展,提供一校三院同仁醫藥品研發服務,以開發具有創新性與前瞻性之生技醫藥產品開發為宗旨。

背景:

生技醫藥為我國重要產業,建立藥品及醫材開發的關鍵價值鏈平台是校園研究成果產業化最大的助力。為有效統整及加速本校之新藥及醫材研發能量,規劃成立臺北醫學大學生技醫藥商品化中心(TMU Biomedical Commercialization Center),藉由商品化中心跨院系所專業團隊間的整合運作,提供一校三院同仁生技藥品臨床前到IND申請之臨床前研究(pre-clinical study)諮詢與服務。此外,透過北醫事業發展處協助醫藥品商品化開發策略,包含藥物市場定位分析,法規、專利檢索和諮詢服務,技術轉移或尋求業界承接產學合作案,及衍生新創事業體之相關規劃。

目的:

整合新藥開發及醫療器材從臨床前研究到IND/IDE所需之技術發展平台(Research Development),提供校內外單位委託合作或共同開發之服務。

搭配事業發展處之資源協助擬定生技醫藥品商業化發展策略(Business Development)、專利布局及商業化輔導,以加速產出具有創新性與前瞻性的生技醫藥品。

初期以藥品的商業化平台為目標:規劃由藥物設計/合成與篩選、藥理活性、藥物動力學、藥物代謝、藥效、毒理、小試量產、製劑開發等提供平台服務。

Fingerprint Dive into the research topics where TMU Biomedical Commercialization Center is active. These topic labels come from the works of this organisation's members. Together they form a unique fingerprint.

Histone Deacetylase Inhibitors Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Cells Chemical Compounds
Histone Deacetylases Medicine & Life Sciences
Apoptosis Medicine & Life Sciences
Mucocutaneous Lymph Node Syndrome Medicine & Life Sciences
Tubulin Medicine & Life Sciences
Inhibitory Concentration 50 Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2010 2020

抗熱休克蛋白抑制劑:以嘧啶為骨架利用有機金屬耦合反應合成系列衍生物

Liu, Y.

8/1/197/1/20

Project: A - Government Institutionb - Ministry of Science and Technology

利用組蛋白去乙醯?抑制劑以增強免疫檢查點抑制劑效用及其機制探討

Huang, H.

8/1/197/1/20

Project: A - Government Institutionb - Ministry of Science and Technology

Research Output 1996 2019

3 Citations (Scopus)

1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase

Lai, M. J., Ojha, R., Lin, M. H., Liu, Y. M., Lee, H. Y., Lin, T. E., Hsu, K. C., Chang, C. Y., Chen, M. C., Nepali, K., Chang, J. Y. & Liou, J. P., Jan 15 2019, In : European Journal of Medicinal Chemistry. 162, p. 612-630 19 p.

Research output: Contribution to journalArticle

Benzamides
Histone Deacetylases
Tubulin
Heterografts
Inhibitory Concentration 50
Growth Inhibitors
Amides
Prostatic Neoplasms
Cells
Lead compounds
2 Citations (Scopus)

Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo

Hsieh, Y. L., Tu, H. J., Pan, S. L., Liou, J. P. & Yang, C. R., Jun 1 2019, In : Biochimica et Biophysica Acta - Molecular Cell Research. 1866, 6, p. 992-1003 12 p.

Research output: Contribution to journalArticle

Triple Negative Breast Neoplasms
Histone Deacetylase Inhibitors
Breast Neoplasms
Histone Deacetylases
Acetylation